These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22850772)

  • 41. Off-label promotion.
    Somberg J
    Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
    [No Abstract]   [Full Text] [Related]  

  • 42. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
    [No Abstract]   [Full Text] [Related]  

  • 43. Sandoz sues FDA over delay in first biogeneric approval.
    Fox JL
    Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046
    [No Abstract]   [Full Text] [Related]  

  • 44. FDA to steer nanotech.
    Fox JL
    Nat Biotechnol; 2008 Oct; 26(10):1060. PubMed ID: 18846060
    [No Abstract]   [Full Text] [Related]  

  • 45. Access to safety data--stockholders versus prescribers.
    Pfeffer MA; Bowler MB
    N Engl J Med; 2011 Jul; 365(1):1-3. PubMed ID: 21714642
    [No Abstract]   [Full Text] [Related]  

  • 46. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 47. Has the FDA Amendments Act of 2007 impaired drug development?
    Franson TR
    Clin Pharmacol Ther; 2011 Feb; 89(2):169-71. PubMed ID: 21252933
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Genta sued over NDA withdrawal.
    Mack GS
    Nat Biotechnol; 2004 Jul; 22(7):788-9. PubMed ID: 15229523
    [No Abstract]   [Full Text] [Related]  

  • 49. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 50. Accelerated approval of oncology drugs: can we do better?
    Ellenberg SS
    J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401
    [No Abstract]   [Full Text] [Related]  

  • 51. Pharmaceuticals and medical devices: FDA oversight.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2009 Jan; ():1-28. PubMed ID: 19297718
    [No Abstract]   [Full Text] [Related]  

  • 52. Ensuring the safety of genotech drugs through implied warranty theory.
    Serra WM
    Am J Law Med; 1997; 23(2-3):363-81. PubMed ID: 9262761
    [No Abstract]   [Full Text] [Related]  

  • 53. Access before approval--a right to take experimental drugs?
    Okie S
    N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
    [No Abstract]   [Full Text] [Related]  

  • 54. New FDA law will help preserve production of "life-saving" drugs.
    Thompson CA
    Am J Health Syst Pharm; 2012 Aug; 69(16):1352, 1354. PubMed ID: 22855095
    [No Abstract]   [Full Text] [Related]  

  • 55. Legislation would put drugs and other therapies to a useful test.
    Carroll J
    Manag Care; 2008 May; 17(5):12-3. PubMed ID: 18567462
    [No Abstract]   [Full Text] [Related]  

  • 56. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A; Lauterio TJ; Davis MW
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reforming accelerated approval.
    Nat Biotechnol; 2012 Apr; 30(4):293. PubMed ID: 22491259
    [No Abstract]   [Full Text] [Related]  

  • 58. The impact of FDA reform.
    Trunzo J
    Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Indian company seeks US approval for generic AIDS drugs.
    Nature; 2004 Aug; 430(7001):716. PubMed ID: 15306779
    [No Abstract]   [Full Text] [Related]  

  • 60. Bush tails follow-ons.
    Fox J
    Nat Biotechnol; 2008 Apr; 26(4):366. PubMed ID: 18392007
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.